alphaveASTRAZEN₹6,843.00

AstraZeneca Pharma India Limited

Annual Quarterly₹ CrorePeersSANOFICONR PGHL SANOFI SENORES INNOVACAP MOREPENLAB IOLCP FDCMcap ₹17,108 Cr

View

In ₹ Crore except Per Share 12 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	311.1	305.8	383.2	387.5	408.0	440.3	480.5	526.3	559.1	611.6	578.6	682.8
Other Income	8.4	9.7	8.7	8.3	8.2	8.0	16.2	11.2	6.2	5.1	6.0	9.2
Total Income	319.4	315.4	391.9	395.9	416.2	448.3	496.6	537.6	565.3	616.7	584.6	692.0
Expenses
+ Cost of Materials Consumed	38.8	37.5	33.6	45.9	77.1	69.9	94.3	9.5	0.0	0.0	0.0	0.0
+ Purchases of Stock-in-Trade	139.9	181.5	75.0	240.3	251.9	228.8	287.9	417.6	432.4	697.1	312.3	304.6
+ Changes in Inventories	-56.6	-70.8	105.0	-55.7	-103.1	-51.6	-122.5	-131.7	-107.9	-330.7	81.9	142.6
+ Employee Benefit Expense	65.3	63.2	58.0	61.0	68.0	62.4	66.1	64.5	60.5	93.8	45.7	79.2
+ Finance Costs	0.5	0.6	-0.1	0.1	0.3	0.3	0.7	0.7	0.7	1.1	2.0	2.0
+ Depreciation & Amortisation	3.7	3.7	3.8	3.9	9.3	9.1	17.7	16.6	2.6	3.8	5.6	5.2
+ Other Expenses	70.9	79.2	62.3	58.0	61.5	53.9	68.4	85.3	99.0	106.6	77.8	107.5
Total Expenses	262.5	295.0	337.5	353.5	365.1	372.7	412.5	462.5	487.2	571.6	525.3	641.0
EBITDA	52.8	15.1	49.4	38.1	52.5	77.0	86.4	81.1	75.2	44.8	60.9	48.9
EBIT	49.1	11.4	45.6	34.2	43.2	67.9	68.7	64.5	72.6	41.0	55.3	43.7
Profit
PBT before Exceptional Items	57.0	20.4	54.4	42.4	51.0	75.6	84.2	75.1	78.1	45.1	59.2	51.0
+ Exceptional Items	16.4	0.0	0.0	-57.6	0.0	-33.5	-5.7	-0.4	-5.3	1.5	-1.1	-0.2
Pretax Income	73.4	20.4	54.4	-15.2	51.0	42.0	78.5	74.7	72.8	46.5	58.1	50.8
+ Current Tax	21.3	4.7	15.5	10.8	14.7	12.2	22.9	22.1	19.0	4.0	14.3	10.9
+ Deferred Tax	-0.3	-0.1	-0.6	-14.1	-2.1	-1.0	-2.7	-3.2	-0.4	10.0	-1.1	2.0
Tax Expense	21.0	4.6	14.9	-3.4	12.6	11.2	20.2	18.9	18.6	14.0	13.3	12.8
Net Income	52.4	15.8	39.5	-11.8	38.4	30.9	58.3	55.8	54.2	32.6	44.9	37.9
+ Net Income — Continuing Ops	52.4	15.8	39.5	-11.8	38.4	30.9	58.3	55.8	54.2	32.6	44.9	37.9
+ Other Comprehensive Income	0.3	0.1	0.2	0.7	-1.7	-1.7	1.5	0.6	-0.3	0.0	-4.8	-0.3
Total Comprehensive Income	52.7	15.9	39.7	-11.0	36.8	29.1	59.7	56.4	53.9	32.6	40.1	37.6
Per Share
Basic EPS	20.95	6.32	15.79	-4.72	15.37	12.34	23.30	22.33	21.69	13.04	17.95	15.17
Diluted EPS	20.95	6.32	15.79	-4.72	15.37	12.34	23.30	22.33	21.69	13.04	0.00	0.00
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	1.5	0.6	-0.3	0.0	-4.8	-0.3
+ Items NOT to be Reclassified to P&L	0.4	0.1	0.3	0.7	-2.2	-2.3	2.0	0.8	-0.4	0.0	-6.4	-0.4
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	0.5	0.2	-0.1	0.0	-1.6	-0.1
+ Tax on Items NOT to be Reclassified — alt tag	0.1	0.0	0.1	0.0	-0.6	-0.6	—	—	—	—	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	20.95	6.32	15.79	-4.72	15.37	12.34	23.30	22.33	21.69	13.04	17.95	15.17
Diluted EPS — Continuing Operations	20.95	6.32	15.79	-4.72	15.37	12.34	23.30	22.33	21.69	13.04	0.00	0.00
Regulatory Disclosures — filed alongside, not part of the P&L
Related-party Transactions — During the Period	—	—	—	—	—	—	770.1	—	1,001.3	—	1,070.4	—
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	188.9	157.5	169.6	157.1	182.1	193.2	220.9	230.9	234.6	245.2	184.4	235.6
Gross Margin %	60.74	51.51	44.27	40.54	44.62	43.89	45.97	43.87	41.96	40.09	31.86	34.50
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	57.0	20.4	54.4	42.4	51.0	75.6	84.2	75.1	78.1	45.1	59.2	51.0
− Exceptional Items (reconciliation)	16.4	0.0	0.0	-57.6	0.0	-33.5	-5.7	-0.4	-5.3	1.5	-1.1	-0.2
Net Income Adj (tax-effected)	40.6	15.8	39.5	33.0	38.4	55.5	62.5	56.1	58.2	31.6	45.7	38.1
EPS Adj	16.26	6.32	15.79	13.21	15.37	22.19	24.99	22.44	23.27	12.63	18.28	15.24
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Paid Up Equity Capital	5.0	5.0	5.0	5.0	5.0	5.0	5.0	5.0	5.0	5.0	5.0	5.0

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.